--- title: "CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base" type: "News" locale: "en" url: "https://longbridge.com/en/news/278622148.md" description: "CANbridge Pharmaceuticals Inc. has completed a share subscription, issuing 84,033,613 new shares at HK$2.38 each, increasing its total issued share capital to 595,443,347 shares. This transaction raises the new subscriber's stake to 16.26%, while existing major shareholder Baheal's holding is diluted to 16.32%. The deal reshapes the shareholder structure, potentially strengthening the company's financial position but diluting existing shareholders' interests. The latest analyst rating for CANbridge stock is a Buy with a price target of HK$3.00." datetime: "2026-03-10T22:11:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278622148.md) - [en](https://longbridge.com/en/news/278622148.md) - [zh-HK](https://longbridge.com/zh-HK/news/278622148.md) --- # CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential An update from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available. CANbridge Pharmaceuticals has completed a share subscription under its general mandate, issuing 84,033,613 new shares at HK$2.38 each to a single subscriber. The transaction increases the company’s total issued share capital from 511,409,734 to 595,443,347 shares, marking a significant equity raise that broadens its capital base. Following the issuance, the new subscriber’s stake rises from 2.51% to 16.26%, while existing major shareholder Baheal’s holding is diluted from 19.00% to 16.32%. The deal reshapes the company’s shareholder structure, potentially strengthening its financial position but diluting existing shareholders’ percentage interests, and may influence future governance dynamics and market perception. The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page. **More about CANbridge Pharmaceuticals Inc.** CANbridge Pharmaceuticals Inc. is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong under stock code 1228. The company focuses on developing and commercializing innovative therapies, with its shareholder base including founder and chairman Dr. James Qun Xue and strategic investor Baheal, alongside a broad group of public shareholders. **Average Trading Volume:** 3,778,457 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$1.27B ### Related Stocks - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [01228.HK](https://longbridge.com/en/quote/01228.HK.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) ## Related News & Research - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)